Data / Form D filings / Galvanize Therapeutics, Inc.
Galvanize Therapeutics, Inc.: Form D filings
Galvanize Therapeutics, Inc., a biotechnology company in Redwood City, CA, filed 5 Form D notices with the SEC between 2019 and 2025. The latest, on September 11, 2025, reports $96.1 million sold of a $141.1 million offering to 28 investors.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 3200 Bridge Parkway, Redwood City, CA, 94065
- Phone
- (650) 268-4252
- Industry
- Biotechnology
- Entity type
- Corporation
- Incorporated in
- Delaware
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 1659073
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Sep 11, 2025 | New notice | $141,066,486 | $96,130,465 | $44,936,021 | 28 | Jul 7, 2025 | sec.gov |
| Mar 22, 2022 | New notice | $4,000,000 | $4,000,000 | 1 | Mar 9, 2022 | sec.gov | |
| Mar 9, 2022 | New notice | $2,000,000 | $2,000,000 | 1 | Feb 23, 2022 | sec.gov | |
| Nov 18, 2019 | Amendment | $43,000,000 | $42,514,946 | $485,054 | 1 | Oct 8, 2015 | sec.gov |
| Mar 13, 2019 | New notice | $28,000,000 | $27,514,946 | $485,054 | 1 | Oct 8, 2015 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Doug Godshall | Executive Officer, Director | |
| Jonathan Waldstreicher | Executive Officer | |
| Antoine Papiernik | Director | |
| David Lewis | Director | |
| Steve Anheier | Executive Officer | |
| Seth Harrison | Director | |
| Zack Scott | Director |
Other biotechnology companies in California that filed recently
- Trellis Bioscience, Inc. $9.1 million · Oct 29, 2026
- BigHat Biosciences, Inc. $75.1 million · Oct 26, 2026
- Theravie Pharma, Inc. $750,000 · Oct 19, 2026
- Adela, Inc. $12 million · Oct 19, 2026
- Estuary Biotherapeutics, Inc. $40.7 million · Oct 16, 2026
- Renue Life Sciences, Inc. $250,000 · Oct 14, 2026
Every Form D from the week of Sep 8, 2025 · All recent filings in California · All recent Biotechnology filings
Read from SEC EDGAR. Amount sold is what Galvanize Therapeutics, Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.